A phase I trial of Actinium-225 DOTA TLX 592 in patient with prostate cancer
Latest Information Update: 11 Aug 2021
At a glance
- Drugs TLX 592 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 11 Aug 2021 New trial record
Latest Information Update: 11 Aug 2021